Fatty15 (C15:0 / Pentadecanoic Acid)
Episodes covering fatty15 (c15:0 / pentadecanoic acid) — protocols, research, and expert discussions.
Odd-chain saturated fatty acid supplement targeting cellular health, metabolism, and longevity pathways
Fatty15 is built around pentadecanoic acid (C15:0), an odd-chain saturated fatty acid that the company claims is a newly discovered essential fatty acid. The science is genuinely interesting: cell-based studies show C15:0 activates AMPK, inhibits mTOR, and shares activity profiles with longevity drugs like rapamycin.
The observational data is compelling - higher C15:0 levels are consistently associated with lower rates of type 2 diabetes, heart disease, and metabolic conditions across multiple population studies. People in longevity zones like Sardinia have significantly higher C15:0 levels.
The catches:
- Only 2 human RCTs published, with modest results
- Most research is by the company founder
- "Essential fatty acid" status not recognized by National Academies
- No human longevity trials exist
- CSPI (Center for Science in the Public Interest) is skeptical
An intriguing longevity-focused supplement with plausible mechanisms and interesting observational data, but human trial evidence is early-stage. At $49/month, it's a reasonable bet for longevity enthusiasts willing to be early adopters. Not yet proven enough for mainstream recommendation.
Science & Mechanisms
What is C15:0?
Pentadecanoic acid (C15:0) is an odd-chain saturated fatty acid found primarily in: - Dairy fat (butter, whole milk, cheese) - Some fish - Certain plants
Unlike common saturated fats (C16:0, C18:0), C15:0 has an odd number of carbons, giving it different biological properties.
Discovery Story:
C15:0 was identified by Dr. Stephanie Venn-Watson while studying aging in Navy dolphins. Dolphins with higher C15:0 levels had better metabolic health and fewer age-related conditions.
Proposed Mechanisms:
1. Longevity Pathway Activation:
| Pathway | Effect | Significance |
|---|---|---|
| AMPK activation | ↑ | Energy sensing, autophagy |
| mTOR inhibition | ↓ | Matches caloric restriction effects |
| PPARα/δ agonist | ↑ | Metabolic regulation |
These pathways are the same ones targeted by longevity drugs like rapamycin and metformin.
2. Cell Membrane Integration:
- Incorporates into cell membranes
- May improve membrane stability
- Supports mitochondrial function
3. Anti-inflammatory Effects:
- Reduces MCP-1, TNF-α, IL-10
- Comparable to rapamycin in cell studies
Key Research:
Cell-Based Studies (Favorable):
- Venn-Watson 2023: C15:0 matched rapamycin in 24/36 cell-based activities including anti-inflammatory and anticancer effects
Observational Studies (Consistent):
- Higher C15:0 → lower type 2 diabetes risk
- Higher C15:0 → lower cardiovascular disease
- Higher C15:0 → lower NAFLD/NASH
- Sardinian longevity zone: Higher C15:0 levels
Human RCTs (Limited):
- TANGO Trial 2024: 300mg C15:0 + Mediterranean diet modestly reduced LDL in women with NAFLD, but not significantly better than diet alone (except for LDL)
- 2024 Overweight/Obesity Trial: Showed plasma C15:0 increases with supplementation
The "Essential" Debate:
Fatty15 claims C15:0 is essential (must come from diet). The criteria: - Not synthesized in sufficient quantities endogenously ✓ - Required for physiological health - unclear
The National Academies of Science does not recognize C15:0 as essential. A 2024 review called it a "potential candidate" needing more research.
Episodes
Lucas Aoun interviews Stephanie Venn-Watson, the researcher who discovered pentadecanoic acid (C15:0) through studying longevity biomarkers in dolphins. Venn-Watson explains how...
Simon Hill critically examines the Fatty15 supplement with lipid researcher Bill Harris. They evaluate whether C15:0 qualifies as an essential fatty acid, scrutinize the quality...
This episode explores C15:0 and Fatty15 through a functional medicine lens, examining how odd-chain fatty acids differ from standard even-chain saturated fats in their metabolic...
Both Fatty15 founders share the story of discovering C15:0 through Navy dolphin research. They explain how pentadecanoic acid was found to be the strongest predictor of healthy ...
Nutrition Diva provides a consumer-oriented evaluation of Fatty15, breaking down what C15:0 is and whether supplementation is necessary. The episode covers the dietary sources o...
Dr. Stephanie Venn-Watson dives deep into the metabolic pathways affected by C15:0 on The Metabolic Link. She explains how pentadecanoic acid activates AMPK and inhibits mTOR, s...
Both Venn-Watson founders discuss how their Navy dolphin research led to the discovery of C15:0 as a longevity biomarker. They share the full story from dolphin health monitorin...
GW Integrative Medicine explores the connection between dolphin research and anti-aging with Fatty15 founder Stephanie Venn-Watson. The episode covers how C15:0 was identified a...
The Gladden Longevity Podcast explores the dolphin research behind C15:0 with Dr. Stephanie Venn-Watson. The discussion covers how marine biology research yielded insights into ...
The Venn-Watson team shares how their work helping Navy dolphins led to the discovery of C15:0 and the creation of Fatty15. The episode covers the origin story, the surprising f...